HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Core Assets of Southward Funds

1,123.620

-2.229-0.20%

Number of Gainers:21

Number of Losers:40

Number of Flat:6

PE:- -

High:1,130.772

Open:1,125.841

Low:1,108.835

Close:1,125.849

Loading ...

Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting

Top Win Unveils Strategic Investments And Ticker Change To Drive Digital Assets Innovation In Asia

HKEX Sanctions Former China Health Technology Directors

MT Newswires Live

XD Inc. Conducted Annual General Meeting

Hansoh Pharmaceutical Group Announces NMPA Approval for Clinical Trials of Innovative HS-10510 Tablets

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10510 Tablets Issued by Nmpa

THOMSON REUTERS

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-20118 Tablets Issued by Nmpa

THOMSON REUTERS

AviChina Industry & Technology Co. Ltd. Announces 2024 Final Dividend of RMB0.081 Per Share

Investors Might Be Too Optimistic on Xiaomi's EV Business -- Market Talk

Innovent Biologics Initiates Phase 3 Trial of Picankibart for Psoriasis Patients with Prior Inadequate Anti-IL-17 Response

Innovent Announces a Phase 3 Study of Picankibart (Anti-Il-23P19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients With Prior Inadequate Response to Anti-Il-17 Antibodies

THOMSON REUTERS

Amer Sports Inc. Announces Secondary Offering of 35 Million Ordinary Shares

China Resources Gas Group Ltd. Conducted AGM

A-Living Smart City Services Co. Ltd. Convened Annual General Meeting

Xiaomi Corporation Unveils New Compensation Plan with Award Shares and XMHK Options for Employees and Service Providers

Tencent Bought Back 985,000 Shares for HK$500.5 Mln on May 28 - HKEX Filing

THOMSON REUTERS

Shandong Weigao Group Announces Leadership Change: Yan Xia Appointed as New Vice Chairman

Kingsoft - Qtrly Profit Attributable RMB283.9 Mln

THOMSON REUTERS

Shandong Weigao Group Medical Polymer - Tang Zhengpeng Has Resigned as Vice-Chairman

THOMSON REUTERS

Sino Biopharm Presents Cancer Drug Data at Oncology Conference

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1589/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1589","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1589\",,,,,undefined,":{"symbol":"BK1589","market":"HK","secType":"PLATE","nameCN":"Core Assets of Southward Funds","latestPrice":1123.62,"timestamp":1749197315293,"preClose":1125.8485,"halted":0,"volume":1909162160,"delay":0,"changeRate":-0.001979,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-2.228516,"latestTime":"06-06 16:00:00","open":1125.8408,"high":1130.7719,"low":1108.8348,"amount":50411219924.9,"amplitude":0.019485,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":2.106,"peRate":17.544731,"turnoverRate":0.003411,"increases":20,"decrements":44,"flats":3,"marketCap":15678420809216,"floatMarketCap":14660641200640},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1589\",,,,,undefined,":{"symbol":"BK1589","high":1130.7719,"amplitude":0.019485,"preClose":1125.8485,"low":1108.8348,"pbRate":"2.106","latestPrice":1123.62,"volume":1909162160,"delay":0,"open":1125.8408,"prevYearClose":949.2231,"prevWeekClose":1095.019,"prevMonthClose":1095.019,"prevQuarterClose":1071.805,"fiveDayClose":1095.019,"twentyDayClose":1067.642,"sixtyDayClose":1138.122,"secType":"PLATE","market":"HK","turnoverRate":0.003411,"peRate":17.544731,"marketCap":15678420809216,"floatMarketCap":14660641200640,"timestamp":1749197315293,"nameCN":"Core Assets of Southward Funds"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1589\",,,,undefined,":{"bkCode":"BK1589","up":21,"down":40,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1589\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539250463","title":"Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250463","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250463?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:23","pubTimestamp":1748521386,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLbJ1hqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","BK1521","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1515","BK1589","BK1191","01177"],"gpt_icon":0},{"id":"2539250901","title":"Top Win Unveils Strategic Investments And Ticker Change To Drive Digital Assets Innovation In Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250901","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250901?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:20","pubTimestamp":1748521211,"startTime":"0","endTime":"0","summary":"May 29 (Reuters) - :*TOP WIN UNVEILS STRATEGIC INVESTMENTS AND TICKER CHANGE TO DRIVE DIGITAL ASSETS INNOVATION IN ASIA*TOP WIN INTERNATIONAL LTD: APPOINTED JASON FANG AS CHAIRMAN OF BOARD*TOP WIN INT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nRSD4WS1pb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2539225785","title":"HKEX Sanctions Former China Health Technology Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2539225785","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539225785?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:39","pubTimestamp":1748518792,"startTime":"0","endTime":"0","summary":"The Stock Exchange of Hong Kong  has issued a Statement of Disciplinary Action against two former directors of China Health Technology , according to its Wednesday bourse filing.The duo namely Wang Yue, a former executive director, and Tian Guangmei, a former independent non-executive director, have been censured and deemed unsuitable to hold director or senior management positions.This Director Unsuitability Statement signifies HKEX's opinion that the two are unfit for such roles within the company or its subsidiaries.The Listing Committee found Mr. Wang breached Rule 3.08 regarding certain loans, while both Mr. Wang and Ms. Tian breached rules by failing to cooperate in the Division's investigation concerning a disposal.Their actions were deemed a serious failure to discharge their responsibilities under the Listing Rules. It is clarified that these sanctions apply solely to the two named former directors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0577902371.SGD","LU0540923850.HKD","SG9999002463.SGD","BK1131","SG9999004220.SGD","LU1282649810.SGD","HEXmain","01069","LU1044875133.USD","LU0196878994.USD","SG9999001846.SGD","LU0384037296.USD","LU0648948544.HKD","LU1044874839.SGD","HKXCY","LU0831103253.SGD","LU1242518857.USD","LU0762541174.USD","LU0417516738.SGD","LU0577902538.SGD","LU1642822792.SGD","LU1105468828.SGD","LU1282649141.HKD","LU0791590937.USD","LU1282649067.USD","LU0572944931.SGD","LU0043850808.USD","LU0762540952.USD","LU1481107354.HKD","LU0140636845.USD","LU1831875114.USD","LU0607220059.USD","LU1226287529.USD","IE00BZ08YT58.USD","LU0261947096.USD","LU0873338254.USD","00388","LU0594300419.USD","LU0791591158.USD","LU0979878070.USD","SG9999001093.SGD","LU0417516902.SGD","LU0630378692.HKD","LU1366334651.USD","LU0561508036.HKD","80388","LU1504937902.USD","IE00BKZH1Z71.USD","LU0501845795.SGD","BK1589"],"gpt_icon":1},{"id":"2539252748","title":"XD Inc. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539252748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539252748?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:30","pubTimestamp":1748518245,"startTime":"0","endTime":"0","summary":"XD Inc. held its Annual General Meeting on May 29, 2025, in Shanghai, China. During the meeting, several proposals were presented and approved. The audited consolidated financial statements and reports for the year ended December 31, 2024, were received and considered. A final dividend of HK$0.4 per ordinary share for the year ended December 31, 2024, was declared. Additionally, Mr. Huang Yimeng and Mr. Dai Yunjie were re-elected as executive Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XD Inc. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL1CfgLt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1104","BK1579","BK1615","BK1591","BK1531","BK1608","BK1589","02400"],"gpt_icon":0},{"id":"2539251024","title":"Hansoh Pharmaceutical Group Announces NMPA Approval for Clinical Trials of Innovative HS-10510 Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2539251024","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539251024?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:46","pubTimestamp":1748515588,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL4p4zJp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2539591292","title":"Hansoh Pharmaceutical -  Clinical Trial Approval for Hs-10510 Tablets Issued by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2539591292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539591292?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:15","pubTimestamp":1748513749,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S110B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"2539821259","title":"Hansoh Pharmaceutical - Clinical Trial Approval for Hs-20118 Tablets Issued by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2539821259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539821259?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:06","pubTimestamp":1748513210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S10SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03692","BK1583","BK1589"],"gpt_icon":0},{"id":"2539232424","title":"AviChina Industry & Technology Co. Ltd. Announces 2024 Final Dividend of RMB0.081 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2539232424","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539232424?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:40","pubTimestamp":1748508059,"startTime":"0","endTime":"0","summary":"AviChina Industry & Technology Co. Ltd. has announced a final dividend of RMB0.081 per share for the year ended 31 December 2024. The dividend payment is scheduled for 25 June 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AviChina Industry & Technology Co. Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL7pJVTh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","02357","BK1211"],"gpt_icon":0},{"id":"2539232442","title":"Investors Might Be Too Optimistic on Xiaomi's EV Business -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2539232442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539232442?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:34","pubTimestamp":1748507640,"startTime":"0","endTime":"0","summary":"0834 GMT - Investors may be too optimistic on Xiaomi's electric-vehicle business, to which Morningstar analysts don't assign a moat, they write in a note. Xiaomi's shares are overvalued, with the current P/E ratio of around 40 times well above the low-double-digit historical range, they say. The company aims to expand its EV sales from the domestic market to overseas markets by 2027, they say. The second phase of Xiaomi's EV plant is under construction and may be completed by mid-June this year, they add. Xiaomi would need to increase its production rate from around 25,000 units per month in 1Q to at least 30,000 units per month to hit its unchanged annual target of 350,000 units for 2025, they say. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIUmain","BK1589","BK1607","LU2097828474.EUR","LU2257852520.SGD","LU0359201612.USD","LU0164865239.USD","LU0634319403.HKD","LU1770034418.SGD","LU2039709279.SGD","01810","LU1323998911.USD","LU0345776255.USD","LU1481107354.HKD","LU1770036033.HKD","LU0708995583.HKD","LU2476274308.USD","LU0164880469.USD","SG9999003461.SGD","BK1618","BK1502","HXXD.SI","IE0032431581.USD","LU0823397103.USD","81810","BK1193","LU0456827905.SGD","LU1880383366.USD","BK1575","LU2097828805.USD","LU0823426480.USD","LU1719994722.HKD","LU0918141887.USD","LU0417516902.SGD","LU1794554557.SGD","LU0797268264.HKD","LU0051755006.USD","LU0823038988.USD","LU0456846285.SGD","LU0588546209.SGD","LU1720050803.USD","LU1023057109.AUD","ISBC","LU0314109678.HKD","LU2097828631.EUR","BK1615","LU2097828557.USD","LU1956131251.USD","BK1506","XIACY"],"gpt_icon":1},{"id":"2539868342","title":"Innovent Biologics Initiates Phase 3 Trial of Picankibart for Psoriasis Patients with Prior Inadequate Anti-IL-17 Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2539868342","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539868342?lang=en_us&edition=fundamental","pubTime":"2025-05-29 09:33","pubTimestamp":1748482418,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. Announces Phase 3 Clinical Study of Picankibart for Psoriasis Innovent Biologics, Inc. has announced the initiation of a Phase 3 clinical study to evaluate picankibart, an anti-IL-23p19 antibody, in treating psoriasis patients who have had an inadequate response to anti-IL-17 antibodies. The study recently completed the first participant dosing and is the first of its kind to explore biologics switching in this patient population. The trial will compare the efficacy of picankibart against IL-17 inhibitors. Previous Phase 2 data indicated that picankibart achieved significant skin lesion clearance in 64.6% of patients after 16 weeks. The study aims to provide clinical evidence supporting picankibart's use as an alternative treatment option for challenging cases of psoriasis. Innovent's new drug application for picankibart for moderate-to-severe plaque psoriasis is currently under review by the NMPA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL5yWrZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01801","LU2488822045.USD","LU1969619763.USD","01911","BK1161","LU2328871848.SGD","BK1589","BK1147"],"gpt_icon":0},{"id":"2539891286","title":"Innovent Announces a Phase 3 Study of Picankibart (Anti-Il-23P19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients With Prior Inadequate Response to Anti-Il-17 Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2539891286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539891286?lang=en_us&edition=fundamental","pubTime":"2025-05-29 09:33","pubTimestamp":1748482401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4VKCRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","LU2488822045.USD","LU1969619763.USD","BK1589","LU2328871848.SGD","01801"],"gpt_icon":0},{"id":"2539401187","title":"Amer Sports Inc. Announces Secondary Offering of 35 Million Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2539401187","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539401187?lang=en_us&edition=fundamental","pubTime":"2025-05-29 04:55","pubTimestamp":1748465713,"startTime":"0","endTime":"0","summary":"Amer Sports Inc. has announced a secondary offering of 35 million ordinary shares by entities affiliated with FountainVest Partners. The company itself will not sell any shares and will not receive any proceeds from this offering. Goldman Sachs & Co. LLC and BofA Securities are the lead book-running managers for the offering, which is subject to market conditions. Interested investors are advised to read the related prospectus filed with the SEC for detailed information about the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amer Sports Inc. published the original content used to generate this news brief via Business Wire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL11n1ld:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU1894683264.USD","LU0130102774.USD","IE00BSNM7G36.USD","LU0326950275.SGD","LU0261950470.USD","IE00BFXG1179.USD","LU0787776722.HKD","BK4588","LU2237443622.USD","LU0048573561.USD","BK4504","AS","LU0096364046.USD","BK4202","LU2237443465.HKD","LU0742534661.SGD","82020","BK4553","LU0251142724.SGD","LU0477156797.USD","IE0004086264.USD","LU1162221912.USD","LU0251131958.USD","LU2129689514.USD","LU0320765489.SGD","BAC","LU0320765646.SGD","LU2133065610.SGD","ANPDY","BK1589","BK4127","LU1718418525.SGD","LU1201861249.SGD","LU1280957306.USD","IE00BLSP4452.SGD","LU0048597586.USD","LU0244354667.USD","LU0321505439.SGD","02020","LU2237438978.USD","LU1894683348.USD","BK1502","LU1868836591.USD","LU0605514214.HKD","LU0868494617.USD","IE00B19Z3B42.SGD","LU0417517546.SGD","BK4207","LU0140636845.USD"],"gpt_icon":0},{"id":"2538476937","title":"China Resources Gas Group Ltd. Conducted AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2538476937","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538476937?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:42","pubTimestamp":1748436140,"startTime":"0","endTime":"0","summary":"China Resources Gas Group Ltd. held its annual general meeting on 28 May 2025. All proposed resolutions were approved, except for the resolution related to the retirement of Mr. WANG Gaoqiang, which was withdrawn.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Gas Group Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL5CT96:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","IE00BGHQDM52.EUR","01193","LU0348825331.USD","BK1566","IE00BVYPNP33.GBP","LU0417516738.SGD","BK1589","BK1570","LU0348735423.USD","IE00BVYPNQ40.USD","BK1221"],"gpt_icon":0},{"id":"2538475885","title":"A-Living Smart City Services Co. Ltd. Convened Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538475885","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538475885?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:03","pubTimestamp":1748433806,"startTime":"0","endTime":"0","summary":"A-Living Smart City Services Co. Ltd. held its 2024 Annual General Meeting on 28 May 2025. During the meeting, several proposals were put forward and approved, including the distribution of a final dividend, the appointment of an executive director, changes to the members of board committees, and the obtaining of a general mandate to buy back H shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. A-Living Smart City Services Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL5XKkz5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03383","BK1555","BK1229","BK1542","03319","BK1240","BK1258","BK1589"],"gpt_icon":0},{"id":"2538730504","title":"Xiaomi Corporation Unveils New Compensation Plan with Award Shares and XMHK Options for Employees and Service Providers","url":"https://stock-news.laohu8.com/highlight/detail?id=2538730504","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538730504?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:01","pubTimestamp":1748433711,"startTime":"0","endTime":"0","summary":"Xiaomi Corporation has announced the grant of awards under its 2023 Share Scheme and XMHK Options under the 2024 Xiaomi HK Share Scheme. On May 28, 2025, the company awarded a total of 30,827,078 shares to 1,615 selected participants, including employees and service providers, under the 2023 Share Scheme. Additionally, Xiaomi HK granted 1,423,271 options to four selected employees under the 2024 scheme. These moves are part of Xiaomi's strategic initiatives to enhance its compensation plans for eligible participants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xiaomi Corporation published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL4344lh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1575","BK1615","LU1794554557.SGD","LU0823039010.USD","LU0348735423.USD","LU0700851271.USD","IE0032431581.USD","BK1502","LU2097828474.EUR","LU0051755006.USD","LU0823413660.USD","LU0320764599.SGD","81810","LU0871576103.HKD","LU1961090484.USD","LU0314109678.HKD","LU0918141887.USD","LU1481107354.HKD","HXXD.SI","LU0235996351.USD","LU1956131251.USD","LU0052750758.USD","LU2097828805.USD","BK1589","LU0572944931.SGD","XIACY","01810","LU0593848301.USD","LU1880383440.USD","MIUmain","LU0327786744.USD","LU0531971595.HKD","LU0823426308.USD","LU1251922891.USD","LU2097828557.USD","LU0348816934.USD","LU2039709279.SGD","BK1523","LU0359202008.SGD","LU0823038988.USD","LU2476274720.SGD","BK1607","LU0164880469.USD","LU0823413587.USD","BK1618","LU0797268264.HKD","SG9999003461.SGD","LU2778985437.USD","LU1282648689.USD","LU0348814723.USD"],"gpt_icon":1},{"id":"2538242484","title":"Tencent Bought Back 985,000 Shares for HK$500.5 Mln on May 28 - HKEX Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2538242484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538242484?lang=en_us&edition=fundamental","pubTime":"2025-05-28 17:46","pubTimestamp":1748425618,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0577902454.USD","TCHmain","LU1105468828.SGD","LU0106252389.USD","LU0192582467.USD","LU1481107354.HKD","BK1589","LU1804176565.USD","LU0516422440.USD","LU2226246903.HKD","LU1981816686.USD","LU0328353924.USD","LU0918141705.HKD","LU0823426308.USD","IE0009570106.USD","BK1586","LU0541502299.USD","LU1226287875.USD","LU0348825331.USD","LU0499858438.USD","LU0823397285.USD","00700","LU1152091168.USD","LU0128522157.USD","SG9999007991.SGD","LU0067412154.USD","IE00B031HW06.USD","LU2265009873.SGD","LU0531971595.HKD","LU0738912210.USD","LU1439103000.SGD","LU0561508036.HKD","LU0873338254.USD","IE00B97KM107.HKD","LU2237443382.USD","LU1044874839.SGD","LU0516423091.SGD","LU2097828714.EUR","SG9999018865.SGD","IE0008368411.USD","LU0107464264.USD","LU0650527681.SGD","LU1366334651.USD","HTCD.SI","LU1242518931.SGD","LU0348735423.USD","LU0396098781.USD","LU0862451753.SGD","LU0449509016.USD","LU0048388663.USD"],"gpt_icon":0},{"id":"2538428472","title":"Shandong Weigao Group Announces Leadership Change: Yan Xia Appointed as New Vice Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2538428472","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538428472?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:35","pubTimestamp":1748421300,"startTime":"0","endTime":"0","summary":"Shandong Weigao Group Medical Polymer Co. Ltd. announced management changes effective 28 May 2025. Mr. Tang Zhengpeng has resigned as Vice-Chairman but will continue as a non-executive Director and remain a member of the audit, remuneration, and nomination committees. Ms. Yan Xia, previously a non-executive Director, will succeed Mr. Tang as the new Vice-Chairman.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Weigao Group Medical Polymer Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL69f7gR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01066","BK1589","BK1222","LU0287142896.SGD","LU0173614495.USD"],"gpt_icon":0},{"id":"2538448428","title":"Kingsoft - Qtrly Profit Attributable RMB283.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2538448428","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538448428?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:33","pubTimestamp":1748421186,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00PJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1518","BK1589","BK1531","BK1104","BK1517","BK1586","BK1613","BK1526","03888","BK1607"],"gpt_icon":0},{"id":"2538428414","title":"Shandong Weigao Group Medical Polymer - Tang Zhengpeng Has Resigned as Vice-Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2538428414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538428414?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:32","pubTimestamp":1748421166,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00V6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01066","BK1589","LU0287142896.SGD","BK1222","LU0173614495.USD"],"gpt_icon":0},{"id":"2538445804","title":"Sino Biopharm Presents Cancer Drug Data at Oncology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538445804","media":"MT Newswires Live","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538445804?lang=en_us&edition=fundamental","pubTime":"2025-05-28 15:13","pubTimestamp":1748416438,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  presented preliminary data from its first-in-human Phase I clinical study of cancer drug TQB2102 at the 2025 ASCO Annual Meeting, according to a Tuesday filing with the Hong Kong Exchange.The company reported encouraging results, with response rates of up to 70% in certain HER2-positive cancers, including breast and gastric cancers -- even among patients who had not responded to prior treatments.Side effects were described as manageable, with only a few cases of serious lung-related adverse events.TQB2102 is currently in Phase 3 trials and, if successful, could become the world's first approved bispecific HER2 antibody-drug conjugate , the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","01177","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK4231","ADC.AU","BK1521","BK1589","BK1191","BK7095","IE00BZ08YS42.EUR","BK4080","BK1515"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":146,"code":"91000000","status":"200"}]}}